Children with the common inherited disorder neurofibromatosis, type 1 (NF1) are predisposed to myeloid leukemia, particularly juvenile chronic myelogenous leukemia (JCML). The NF1 gene (NF1) encodes a protein called neurofibromin that stimulates the GTPase activity of the p21 ras (Ras) family of signaling proteins. This activity of neurofibromin suggested that NF1 might function as a tumor-suppressor gene in myeloid cells by negatively regulating Ras. Genetic and biochemical data from the laboratory support this hypothesis. The investigators have developed a murine model to investigate the role of NF1 in myeloid growth control. This translational research project is based on laboratory data which suggest that deregulated signaling through the Ras pathway in response to granulocyte macrophage colony stimulating factor (GM-CSF) plays a central role in the over-proliferation of myeloid cells that is characteristic of murine NF1-/- fetal liver cells and JCML bone marrow cells. This proposal has 3 specific aims. The experiments proposed under aim 1 will provide a rigorous genetic test of the hypothesis that the deregulated growth of NF1-/- cells is GM-CSF-specific. The experiments proposed in aim 2 are based on genetic and biochemical evidence that hyperactive Ras plays a central role in the aberrant phenotype of murine Nf1-/- and human JCML cells. These mechanistic data suggest that drugs that target the Ras pathway are rational potential theraeputics for JCML and other myeloid leukemias. Mice reconstituted with Nf1-/- fetal liver cells provide a genetically-defined in vivo model system to test this hypothesis. The third experimental aim will involve characterizing the germ line and somatic NF1 mutations that exist in children with leukemia as these data may provide novel insights into mechanisms of normal growth control and tumorigenesis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA072614-05S1
Application #
6435386
Study Section
Pathology B Study Section (PTHB)
Program Officer
Mietz, Judy
Project Start
1997-02-15
Project End
2002-01-31
Budget Start
2001-02-01
Budget End
2002-01-31
Support Year
5
Fiscal Year
2001
Total Cost
$36,409
Indirect Cost
Name
University of California San Francisco
Department
Pediatrics
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Burgess, Michael R; Hwang, Eugene; Mroue, Rana et al. (2017) KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer. Cell 168:817-829.e15
North, Matthew; Shuga, Joe; Fromowitz, Michele et al. (2014) Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke. BMC Cancer 14:6
Diaz-Flores, Ernesto; Goldschmidt, Hana; Depeille, Philippe et al. (2013) PLC-? and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. Sci Signal 6:ra105
Shannon, Kevin; Armstrong, Scott A (2010) Genetics, epigenetics, and leukemia. N Engl J Med 363:2460-1
Loh, Mignon L; Sakai, Debbie S; Flotho, Christian et al. (2009) Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 114:1859-63
Denayer, Ellen; Parret, Annabel; Chmara, Magdalena et al. (2008) Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation. Hum Mutat 29:232-9
Haigis, Kevin M; Kendall, Krystle R; Wang, Yufang et al. (2008) Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 40:600-8
Van Meter, Margaret E M; Diaz-Flores, Ernesto; Archard, Joehleen A et al. (2007) K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood 109:3945-52
Sovik, Oddmund; Schubbert, Suzanne; Houge, Gunnar et al. (2007) De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. J Med Genet 44:e84
Diaz-Flores, Ernesto; Shannon, Kevin (2007) Targeting oncogenic Ras. Genes Dev 21:1989-92

Showing the most recent 10 out of 43 publications